Northwest Biotherapeutics reported $4.56M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Agenus USD 18.74M 16.26M Jun/2026
AstraZeneca USD 4.89B 2.67B Jun/2026
Bristol-Myers Squibb USD 8.72B 852M Jun/2026
Celldex Therapeutics USD 47.45M 11.72M Jun/2026
Eisai JPY 245.42B 56.22B Mar/2026
Merck USD 6.85B 1.52B Jun/2026
Northwest Biotherapeutics USD 4.56M 244K Sep/2025
Pfizer USD 976M 727M Jun/2026
Plus Therapeutics USD 2.37M 656K Jun/2026
Roche Holding CHF 7.55B 579M Jun/2025